# US 2026/0297157 A1 · A t cell receptor recognizing an unmutated foxm1 epitope presented on hla-a*02:01

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0297157 A1
- Document ID: US20260297157A1
- Status: Published application
- Kind: A1
- Application number: 19/135,753
- Filed: 2023-12-07
- Published: 2026-10-01
- Earliest claimed: 2022-12-07
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, the University of Texas System
- Inventors: Alexandre REUBEN; John Victor HEYMACH; Gregory LIZEE; Peixin JIANG; Patrick HWU; Minying ZHANG
- Web page: https://patentgrep.com/patent/US20260297157A1

## CPC

- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4242: {Transcription factors, e.g. SOX or c-MYC}
- A61P 35/00: Antineoplastic agents
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C12N 5/0636: {T lymphocytes}
- A61K 2239/15: Non-antibody based
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize a FOXM1 epitope, such as TCRs that recognize a FOXM1 epitope presented on HLA-A*02:01. Accordingly, aspects of the disclosure relate to an engineered T-cell Receptors (TCRs), nucleic acids encoding the TCRs, and cells comprising the nucleic acids and TCRs with respect to this antigen. Also provided are compositions comprising the cells, nucleic acids, or engineered TCRs of the disclosure, methods of making the cells and methods of using the embodiments of the disclosure for therapeutic treatments.

## Claims

### Claim 1

A polypeptide comprising an antigen binding variable region comprising:
(I) a CDR3 comprising an amino acid sequence with at least 80% sequence identity to CASSYAGPGELFF (SEQ ID NO:15), wherein the variable region comprises a CDR1 with at least 80% sequence identity to MNHEY (SEQ ID NO:13), and wherein the variable region comprises a CDR2 with at least 80% sequence identity to SVGEGT (SEQ ID NO:14); or
(II) a polypeptide comprising an antigen binding variable region comprising a CDR3 comprising an amino acid sequence with at least 80% sequence identity to CAVNKSGFQKLVF (SEQ ID NO:29), wherein the variable region comprises a CDR1 with at least 80% sequence identity to DRGSQS (SEQ ID NO:27), wherein the variable region comprises a CDR2 with at least 80% sequence identity to IYSNGD (SEQ ID NO:28).

### Claim at position 2

-6. (canceled)

### Claim 7 (depends on 1)

The polypeptide of claim 1, wherein the variable region comprises an amino acid sequence with at least 70% sequence identity to SEQ ID NO:1.

### Claim at position 4

-23. (canceled)

### Claim 27

An engineered T-cell Receptor (TCR) comprising a TCR-a polypeptide and a TCR-b polypeptide, wherein the TCR-a polypeptide comprises a CDR3 comprising an amino acid sequence with at least 80% sequence identity to CAYWSVPGGSYIPTF (SEQ ID NO:24) and the TCR-b polypeptide comprises a CDR3 comprising an amino acid sequence with at least 80% sequence identity to CASSLRPGTSIPGELFF (SEQ ID NO:12),
wherein the TCR-a polypeptide comprises a CDR1 with at least 80% sequence identity to SEQ ID NO:27 and/or the TCR-b polypeptide comprises a CDR1 with at least 80% sequence identity to SEQ ID NO:13, and
wherein the TCR-a polypeptide comprises a CDR2 with at least 80% sequence identity to SEQ ID NO:28 and the TCR-b polypeptide comprises a CDR2 with at least 80% sequence identity to SEQ ID NO:14.

### Claim at position 6

-44. (canceled)

### Claim 45

A peptide comprising at least 66% sequence identity to SEQ ID NO:30.

### Claim at position 8

-60. (canceled)

### Claim 61 (depends on 45)

A polypeptide comprising the peptide claim 45.

### Claim 62 (depends on 61)

A composition comprising at least one MHC polypeptide and or peptide comprising at least 66% sequence identity to SEQ ID NO:30 or polypeptide of claim 61.

### Claim at position 11

-68. (canceled)

### Claim 69 (depends on 61)

A molecular complex comprising a peptide comprising at least (a) 66% sequence identity to SEQ ID NO:30 or polypeptide of claim 61 and (b) a MHC polypeptide.

### Claim 70 (depends on 69)

A peptide-specific binding molecule, wherein the molecule specifically binds to a peptide comprising at least 66% sequence identity to SEQ ID NO:30 or a polypeptide comprising the peptide or the molecular complex of claim 69.

### Claim 71

(canceled)

### Claim 72 (depends on 69)

A method of producing peptide-specific immune effector cells, comprising:
(a) obtaining a starting population of immune effector cells; and
(b) contacting the starting population of immune effector cells with a peptide comprising at least 66% sequence identity to SEQ ID NO:30 or a polypeptide comprising the peptide or the molecular complex of claim 69, thereby generating peptide-specific immune effector cells.

### Claim at position 16

-105. (canceled)

### Claim 106 (depends on 61)

A method of cloning a T cell receptor (TCR), the method comprising
(a) obtaining a starting population of immune effector cells;
(b) contacting the starting population of immune effector cells with a peptide comprising at least 66% sequence identity to SEQ ID NO:30 or polypeptide of claim 61, thereby generating peptide-specific immune effector cells;
(c) purifying immune effector cells specific to the peptide,
(d) isolating a TCR sequence from the purified immune effector cells.

### Claim at position 18

-141. (canceled)

### Claim at position 19

141-153. (canceled)

### Claim 142 (depends on 27)

A fusion protein comprising the TCR of claim 27 141 and a CD3 binding region.

### Claim 154 (depends on 1)

A cell comprising the polypeptide of claim 1.

### Claim at position 22

-162. (canceled)

### Claim 163 (depends on 1)

A composition comprising the polypeptide of claim 1.

### Claim at position 24

-171. (canceled)

### Claim 172 (depends on 163)

A method for treating or preventing cancer in a subject comprising administering the composition of claim 163 to a subject in need thereof.

### Claim 173 (depends on 163)

A method of stimulating an immune response in a subject, the method comprising administering the composition of claim 163 to a subject in need thereof.

### Claim at position 27

-185. (canceled)

### Claim 187 (depends on 69)

A method for prognosing a patient or for detecting T cell responses in a patient, the method comprising: contacting a biological sample from the patient with the peptide comprising at least 66% sequence identity to SEQ ID NO:30 or a polypeptide comprising the peptide or the molecular complex of claim 69.

### Claim at position 29

-194. (canceled)

### Claim 195 (depends on 45)

A kit comprising a peptide comprising at least 66% sequence identity to SEQ ID NO:30 or a polypeptide of claim 45 in a container.

### Claim at position 31

-198. (canceled)
